BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 31776133)

  • 1. Gain-of-Function Mutant p53 R273H Interacts with Replicating DNA and PARP1 in Breast Cancer.
    Xiao G; Lundine D; Annor GK; Canar J; Ellison V; Polotskaia A; Donabedian PL; Reiner T; Khramtsova GF; Olopade OI; Mazo A; Bargonetti J
    Cancer Res; 2020 Feb; 80(3):394-405. PubMed ID: 31776133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The C-terminus of Gain-of-Function Mutant p53 R273H Is Required for Association with PARP1 and Poly-ADP-Ribose.
    Lundine D; Annor GK; Chavez V; Maimos S; Syed Z; Jiang S; Ellison V; Bargonetti J
    Mol Cancer Res; 2022 Dec; 20(12):1799-1810. PubMed ID: 36074101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.
    Madorsky Rowdo FP; Xiao G; Khramtsova GF; Nguyen J; Martini R; Stonaker B; Boateng R; Oppong JK; Adjei EK; Awuah B; Kyei I; Aitpillah FS; Adinku MO; Ankomah K; Osei-Bonsu EB; Gyan KK; Altorki NK; Cheng E; Ginter PS; Hoda S; Newman L; Elemento O; Olopade OI; Davis MB; Martin ML; Bargonetti J
    Cancer Lett; 2024 Mar; 584():216608. PubMed ID: 38199587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oligomerization of Mutant p53 R273H is not Required for Gain-of-Function Chromatin Associated Activities.
    Annor GK; Elshabassy N; Lundine D; Conde DG; Xiao G; Ellison V; Bargonetti J
    Front Cell Dev Biol; 2021; 9():772315. PubMed ID: 34881245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteome-wide analysis of mutant p53 targets in breast cancer identifies new levels of gain-of-function that influence PARP, PCNA, and MCM4.
    Polotskaia A; Xiao G; Reynoso K; Martin C; Qiu WG; Hendrickson RC; Bargonetti J
    Proc Natl Acad Sci U S A; 2015 Mar; 112(11):E1220-9. PubMed ID: 25733866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.
    Madorsky Rowdo FP; Xiao G; Khramtsova GF; Nguyen J; Olopade OI; Martini R; Stonaker B; Boateng R; Oppong JK; Adjei EK; Awuah B; Kyei I; Aitpillah FS; Adinku MO; Ankomah K; Osei-Bonsu EB; Gyan KK; Altorki NK; Cheng E; Ginter PS; Hoda S; Newman L; Elemento O; Davis MB; Martin ML; Bargonetti J
    bioRxiv; 2023 Jun; ():. PubMed ID: 38076873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frame-shift mediated reduction of gain-of-function p53 R273H and deletion of the R273H C-terminus in breast cancer cells result in replication-stress sensitivity.
    Ellison V; Annor GK; Freedman C; Xiao G; Lundine D; Freulich E; Prives C; Bargonetti J
    Oncotarget; 2021 Jun; 12(12):1128-1146. PubMed ID: 34136083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hot Spot Mutation in TP53 (R248Q) Causes Oncogenic Gain-of-Function Phenotypes in a Breast Cancer Cell Line Derived from an African American patient.
    Shtraizent N; Matsui H; Polotskaia A; Bargonetti J
    Int J Environ Res Public Health; 2015 Dec; 13(1):ijerph13010022. PubMed ID: 26703669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification, validation, and targeting of the mutant p53-PARP-MCM chromatin axis in triple negative breast cancer.
    Qiu WG; Polotskaia A; Xiao G; Di L; Zhao Y; Hu W; Philip J; Hendrickson RC; Bargonetti J
    NPJ Breast Cancer; 2017; 3():. PubMed ID: 28232952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Triple Negative Breast Cancer with a Nucleus-Directed p53 Tetramerization Domain Peptide.
    Xiao G; Annor GK; Fung K; Keinänen O; Zeglis BM; Bargonetti J
    Mol Pharm; 2021 Jan; 18(1):338-346. PubMed ID: 33289569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A PARP1 PROTAC as a novel strategy against PARP inhibitor resistance via promotion of ferroptosis in p53-positive breast cancer.
    Li G; Lin SS; Yu ZL; Wu XH; Liu JW; Tu GH; Liu QY; Tang YL; Jiang QN; Xu JH; Huang QL; Wu LX
    Biochem Pharmacol; 2022 Dec; 206():115329. PubMed ID: 36309080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting mutant p53 by a SIRT1 activator YK-3-237 inhibits the proliferation of triple-negative breast cancer cells.
    Yi YW; Kang HJ; Kim HJ; Kong Y; Brown ML; Bae I
    Oncotarget; 2013 Jul; 4(7):984-94. PubMed ID: 23846322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of the PARP1, ADP-Ribosylation, and TRIP12 Triad With Markers of Patient Outcome in Human Breast Cancer.
    Krishnan A; Spegg V; Dettwiler S; Schraml P; Moch H; Dedes K; Varga Z; Altmeyer M
    Mod Pathol; 2023 Jul; 36(7):100167. PubMed ID: 36990278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MUC1-C Integrates Chromatin Remodeling and PARP1 Activity in the DNA Damage Response of Triple-Negative Breast Cancer Cells.
    Yamamoto M; Jin C; Hata T; Yasumizu Y; Zhang Y; Hong D; Maeda T; Miyo M; Hiraki M; Suzuki Y; Hinohara K; Rajabi H; Kufe D
    Cancer Res; 2019 Apr; 79(8):2031-2041. PubMed ID: 30824588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Correlation Between PARP1 and BRCA1 in AR Positive Triple-negative Breast Cancer.
    Luo J; Jin J; Yang F; Sun Z; Zhang W; Shi Y; Xu J; Guan X
    Int J Biol Sci; 2016; 12(12):1500-1510. PubMed ID: 27994514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone deacetylase inhibitors suppress mutant p53 transcription via HDAC8/YY1 signals in triple negative breast cancer cells.
    Wang ZT; Chen ZJ; Jiang GM; Wu YM; Liu T; Yi YM; Zeng J; Du J; Wang HS
    Cell Signal; 2016 May; 28(5):506-515. PubMed ID: 26876786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents - A Potential Therapy for Cancer.
    Muvarak NE; Chowdhury K; Xia L; Robert C; Choi EY; Cai Y; Bellani M; Zou Y; Singh ZN; Duong VH; Rutherford T; Nagaria P; Bentzen SM; Seidman MM; Baer MR; Lapidus RG; Baylin SB; Rassool FV
    Cancer Cell; 2016 Oct; 30(4):637-650. PubMed ID: 27728808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 gain-of-function mutations increase Cdc7-dependent replication initiation.
    Datta A; Ghatak D; Das S; Banerjee T; Paul A; Butti R; Gorain M; Ghuwalewala S; Roychowdhury A; Alam SK; Das P; Chatterjee R; Dasgupta M; Panda CK; Kundu GC; Roychoudhury S
    EMBO Rep; 2017 Nov; 18(11):2030-2050. PubMed ID: 28887320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cancer-testis gene,
    Gu Y; Wang C; Zhu R; Yang J; Yuan W; Zhu Y; Zhou Y; Qin N; Shen H; Ma H; Wang H; Liu X; Hu Z
    Cancer Biol Med; 2021 Feb; 18(1):74-87. PubMed ID: 33628586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer.
    Zhou Q; Ji M; Zhou J; Jin J; Xue N; Chen J; Xu B; Chen X
    Biochem Pharmacol; 2016 May; 107():29-40. PubMed ID: 26920250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.